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A molecular and in vivo investigation of advanced prostate cancer: Deconstructing
AMPK activity and developing an improved mouse model

Sandi Robyn Wilkenfeld, BS

Advisory Professor: Daniel Frigo, Ph.D.

ABSTRACT

Prostate cancer is one of the leading causes of cancer-related death in men.
Prostate cancer is dependent on androgen receptor (AR)-mediated pathways, and
AR is therefore targeted to treat advanced prostate cancer. Despite an initial
response to current AR-targeted therapies, patients invariably relapse, due in large
part to the reactivation of AR through a variety of mechanisms. My goal is to identify
pathways downstream of AR that can be therapeutically targeted. We and others
previously demonstrated that in prostate cancer, calcium/calmodulin-dependent
kinase kinase 2 (CaMKK2) is a direct downstream target of AR, and can promote
disease progression through the phosphorylation and activation of the 5’ AMPactivated protein kinase (AMPK). AMPK is a major regulator of cell homeostasis.
While it is well established that AMPK is required for processes like cell growth,
development, and stress response, its role in cancer is enigmatic. AMPK can
promote both oncogenic and tumor suppressive pathways in different contexts,
making it challenging to target for cancer drug development. Interestingly, the α1
and α2 isoforms of the catalytic α subunit of AMPK have been shown to localize to
distinct compartments within the cell, and molecular studies indicate that these
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isoforms have non-redundant functions. Furthermore, subcellular populations of
AMPK behave differently in response to stress. Together, these findings suggest
that separate populations of AMPK within the cell may behave differently,
challenging the dogma of AMPK existing as a single signaling molecule.
In the advanced stages of prostate cancer, the cancer spreads to local and
distant lymph nodes and other organs. Prostate cancer metastasizes primarily to
bone, with up to 90% of men who die of prostate cancer having bone metastases
upon autopsy. A major limitation in the study of advanced prostate cancer is a lack
of relevant preclinical models of disease progression. Rodents are the most
commonly used animal models for studying prostate cancer, and many mouse
models have been developed and are widely used in prostate cancer research.
However, these models typically fail to recapitulate the full progression of prostate
cancer in humans. In fact, there are currently no prostate cancer mouse models that
reliably produce bone metastases at a similar rate to human disease. Given this
issue, I sought to develop a tractable model of mouse prostate cancer metastasis
that consistently metastasizes from the primary site to bone, as it does in human
disease.
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CHAPTER 1: INTRODUCTION

Steroid hormones
Steroid hormones are lipophilic molecules produced in one cell that can
travel great distances within the body to elicit biological effects in another cell. In the
absence of hormone ligand, steroid hormone nuclear receptors (NRs) are
predominantly held in the cytoplasm in an inactive conformation by heat shock
proteins (HSPs). Upon binding ligand, the receptor undergoes a conformational
change that results in the dissociation of HSPs, translocation to the nucleus,
dimerization, association with various co-regulators, and binding to specific
sequences of DNA termed hormone response elements (HREs). This DNA-bound
complex can then regulate the transcription of genes1. It is now realized that steroid
hormones can also activate signal transduction pathways and physiological
changes independent of their actions in the nucleus, via a mechanism designated
non-genomic signaling2. Since this bypasses the process of gene transcription, nongenomic signaling often occurs on a faster time frame and is referred to as rapid or
extranuclear signaling. Rapid signaling often involves NR trafficking to the plasma
membrane, where they can activate kinase pathways either directly or indirectly3,4.
Importantly, non-genomic signaling can also regulate genomic pathways and vice
versa. Hence, the final cellular effect of steroids is often the result of a convergence
of events that began at separate locations.

Classical NR signaling
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Steroid hormones are best known to mediate various physiological cell
functions via genomic activity. In this regard, steroid hormones typically interact with
their cognate receptor in the cytoplasm. This ligand binding results in a
conformational change that leads to the dissociation of heat shock proteins,
translocation of the ligand-bound receptor to the nucleus and homodimerization.
Ligand-bound receptor can then bind to DNA at specific HREs to regulate gene
transcription. Several NRs can also interact indirectly with DNA by tethering to other
transcription factors5. While some steroid hormone-induced nuclear events can
occur in minutes6, typically the genomic effects of steroid hormones take longer,
with changes in gene expression occurring on the timescale of hours7,8.

Prostate cancer progression and treatments
Prostate cancer is the most diagnosed cancer in men, and one of the leading
causes of cancer-related death in men in the United States9. 268,490 new
diagnoses and 34,500 deaths are estimated to occur in 2022 9. If diagnosed early, it
can usually be treated with surgery, radiation therapy, or a combination of
treatments, and the survival rate is high. However, once the cancer has progressed,
it requires a form of hormone therapy called androgen deprivation therapy (ADT),
which includes surgical or chemical castration10. ADT blocks the activation of the
androgen receptor (AR), a nuclear receptor that is the main driver of prostate
cancer, and which initially relies on androgens (ex. testosterone) to propagate its
signal.
While ADT is currently the backbone of almost all treatment regimens for
advanced prostate cancer, there are several problems associated with it. First,
2

resistance to ADT occurs in the majority of patients after several years. Second,
ADT has side effects. ADT can lead to a decrease in bone density, reduced
metabolic and cardiovascular activity, and/or muscle loss among a variety of other
effects11. This is a complicated issue as ADT improves the mortality rate related to
prostate cancer, but increases it as a result of the side effects caused by this
treatment. Fortunately, many of the side effects can be anticipated in advanced and
co-treated proactively if necessary. The negative side effects of ADT as well as
other AR-targeted therapies provide additional rationale to search for
mechanistically novel treatments for CRPC.
ADT initially has a high success rate, which can be increased by the addition
of the chemotherapeutic agent docetaxel or second-generation AR-targeting agents
such as abiraterone and enzalutamide (Harris et al., 2009). However, patients
eventually experience a relapse to ADT-based treatment within 2-3 years, after
which death typically occurs within 18 months12,13. This stage of prostate cancer is
called recurrent or castration-resistant prostate cancer (CRPC), because the
disease is no longer responsive to hormone therapy. Metastases also occur after
the recurrence of disease following hormone deprivation, a stage called metastatic
CRPC (mCRPC). Treatments for advanced prostate cancer include, but are not
limited to, docetaxel as mentioned previously, the antiandrogens abiraterone,
apalutamide, enzalutamide, and darolutamide14, PSMA-targeting agents, PARP
inhibitors, and others. The combination of therapies used for treatment of disease
depends on several factors, including presence of metastases, Gleason score,
presences of genetic alterations (ex. BRCA2), or prostate specific androgen (PSA)
score.
3

Structure of the androgen receptor
The androgen receptor is a transcription factor normally located in the
cytoplasm that is translocated to the nucleus upon activation. The protein structure
of androgen receptors include an N-terminal domain that is responsible for most of
the transcriptional activity, a DNA-binding domain containing two zinc-finger motifs,
and a hinge region that is involved with AR nuclear localization. It also contains a
ligand-binding domain at the C-terminal end, which is the main mechanism of
control of androgen signaling, as it enables binding of the steroid hormones. Once
the AR has entered the nucleus and binds DNA via its DNA binding domain, AR
regulates the expression of hundreds of genes that, in non-transformed tissues, are
involved in normal cell functions, but in prostate cancer cells these genes include
those involved in growth and proliferation15.

AR signaling in advanced prostate cancer
There are several different mechanisms by which cancer cells can overcome
ADT to progress into the castration-resistant stage. In human, castration alone,
either surgical or medical, is not able to remove all of the androgens in the tumor.
Even with this treatment, a certain base level of androgens will be present due in to
the body’s ability to synthesize androgens in the adrenal glands or
intratumorally16,17. Another mechanism prostate cancer cells utilize to circumvent
androgen ablation focuses on the androgen receptors themselves. AR expression
can be increased to mitigate the decrease in androgen presence, as both higher
levels of AR mRNA expression and AR protein levels have been observed in
4

CRPC16. Also, AR splice variants exist which are missing the ligand binding domain,
suggesting the possibility of constitutively active AR even in the absence of
androgens15.
This reactivation of AR signaling pathways, the success of secondgeneration AR-targeting agents such as abiraterone, enzalutamide, apalutamide,
and darolutamide indicate that factors downstream of AR have a role in disease
progression even in CRPC. However, the precise AR-mediated pathways driving
prostate cancer are still poorly understood.

AR-CAMKK2-AMPK signaling axis
One of the genes regulated by AR is the calcium/calmodulin-dependent
kinase kinase 2 (CAMKK2), a serine/threonine kinase which is required for prostate
cancer progression18-21. The protein CAMKK2 encoded by this gene activates
various pathways involved in pro-tumor effects. CAMKK2 expression is increased
as the disease progresses to the castration-resistant stage, while suppression of
CAMKK2 activity results in decreased cancer cell growth and migration in vitro and
in vivo18-21. Furthermore, CAMKK2 expression and activity is increased in response
to androgens in an AR-dependent manner in preclinical models and patients18-21.
CAMKK2 is a serine/threonine kinase that has several known substrates that
mediate its downstream effects. CAMKI and CAMKIV are two downstream targets
that are similarly regulated22. They both are expressed strongly in the brain, but
while CAMKI is expressed throughout all tissue, CAMKIV has a more restricted
expression profile22. AMPK has been identified as another major target of CAMKK2.

5

Since it is both present in the prostate and dependent on CAMKK2 activity, it is
being investigated as a downstream target of CAMKK2.
AMPK (5’ AMP-activated protein kinase) is a serine/threonine kinase with a
major role in maintaining cellular homeostasis23,24. When CAMKK2 is inhibited by
STO-609, the androgen-mediated phosphorylation and activation of AMPK as well
as subsequent cell growth are impaired. Furthermore, androgen-mediated cell
growth is decreased when AMPK is inhibited by siRNA25. Together, these data
show that the AR-CAMKK2-AMPK signaling pathway is important in promoting
prostate cancer progression.

AMPK structure and function
In response to cell stress, AMPK works to maintain homeostasis by
promoting ATP-producing pathways and inhibiting ATP-consuming pathways. As
the AMP/ADP:ATP ratio increases, indicating energetic stress, the regulatory
regions of AMPK become phosphorylated, which increases kinase activity26.
Importantly, AMPK has a known role in cancer and can promote both tumor
suppressive and oncogenic pathways27-31. It was first described as a tumor
suppressor due to its activation by the upstream tumor suppressor LKB132,33.
However, recent data suggests that it may also have an oncogenic role in prostate
cancer, as clinical samples show that its activation increases with disease
progression, and knockdown of AMPK impairs prostate cancer cell growth25.
Furthermore, CAMKK2, not LKB1, is the primary upstream activator of AMPK in
prostate cancer18,34. Together, these findings highlight the complicated role that
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AMPK has in cancer progression and emphasizes the importance of identifying the
mechanism of AMPK activation and how it relates to downstream cancer biology.
AMPK is a heterotrimer composed of a catalytic alpha and regulatory beta
and gamma subunits. The isoforms of each subunit (2 each for alpha and beta, 3 for
gamma) allow for 12 complexes, and potentially more when splice variants are
considered35. Interestingly, the different isoforms of the AMPK subunits may have
non-redundant functions with respect to metabolism, cell structure and function, and
tumorigenesis, both in vitro36-38 and in vivo39-41. The focus of this study is on the
alpha subunit, as it is the catalytic subunit of AMPK. Several studies suggest distinct
functions of the two alpha subunit isoforms (AMPKα1 and AMPKα2) in cell and
mouse models36,41-44, as well as in human tissue45. Genetic analysis of human
prostate tumor samples show that patients with a higher ratio of AMPKα1 relative to
AMPKα2 had a significantly poorer prognosis46. Furthermore, clinical data from
cBioPortal show that across various types of cancers, genomic alterations of
PRKAA1 (gene encoding AMPKα1) are most often amplifications, while genomic
alterations of PRKAA2 (gene encoding AMPKα2) are more often mutations or
deletions. Together, these data suggest that AMPKα1 may have a oncogenic role in
prostate cancer, while AMPKα2 may act more as a tumor suppressor, and that this
effect may be relevant across multiple cancer types beyond prostate cancer.

Compartmentalization of AMPK
Previous evidence from our lab and others shows that AMPK is located in
distinct compartments throughout the cell37,38,45,47-49. This localization may be
dependent on the subunit composition of the heterotrimer. In particular, the
7

localization of the isoforms of the alpha subunit have been studied in various cell
models. The AMPKα1 subunit is predominantly cytoplasmic, while the AMPKα2
subunit can shuttle between the cytoplasm and the nucleus. This is supported by
the presence of a functional nuclear localization sequence only in the AMPKα2
subunit50. Furthermore, isoform localization has been shown to change in response
to certain stimuli51. In particular, we have shown that AMPK spatial dynamics may
change during the onset and progression of prostate cancer as demonstrated by
IHC staining of a tissue microarray of human benign prostate and prostate cancer
tissues25. Staining of p-AMPK in benign tissue was weak, but increased in prostate
cancer. This increase was driven by an enrichment of p-AMPK staining in the
cytoplasm, suggesting that AMPK activation in the cytoplasm may have a role in
prostate cancer progression. Interestingly, the IHC staining of the prostate cancer
tissue microarray also showed possible enrichment of staining of p-AMPK in the
plasma membrane. This is important in light of studies showing that AMPK can be
associated with different membrane-bound compartments, for example the
mitochondria, lysosome, or plasma membrane52-54.

Prostate cancer clinical progression
In the advanced stage of prostate cancer, the cancer has spread to local and
distant lymph nodes and other organs. Prostate cancer metastasizes primarily to
bone, with up to 90% of men who die of prostate cancer having bone metastases
upon autopsy. Besides being a highly painful metastatic site, the prognosis of
prostate cancer patients with bone metastases is much poorer than patients without
metastases55. In prostate cancer, osteoblastic lesions are more common in bone
8

metastases56. This induction of abnormal bone formation can lead to many different
complications.

Preclinical models of prostate cancer
A major limitation in the study of advanced prostate cancer is a lack of
relevant preclinical models of disease progression. Rodents are the most commonly
used animal models for studying prostate cancer, and many mouse models have
been developed and are widely used in prostate cancer research. However, these
models typically fail to recapitulate the full progression of prostate cancer in
humans. In fact, there are currently no prostate cancer mouse models that reliably
produce bone metastases at a similar rate to human disease. Given this issue, I
sought to develop a mouse model of prostate cancer metastasis that consistently
metastasizes from the primary site to the bone, as it does in human disease.
Despite their benefits for use in human cancer research, mice have several
important differences from humans that make it a challenging model for human
prostate cancer. Mice rarely spontaneously develop prostate cancer, and in
common genetically engineered mouse models (GEMMs), the cancer does not
progress similarly to human disease, which often occurs late in life and is initially
slow-progressing. An ideal prostate cancer GEMM would (1) develop as an
adenocarcinoma, (2) be androgen dependent, and (3) metastasize, especially to
bone.
Mouse and human prostates have significant differences anatomically, with the
mouse prostate containing four defined lobes, and the human prostate divided
histologically into four zones. The human prostate is a walnut shaped organ that
9

surrounds the urethra at the base of the bladder. It is divided histologically into three
zones: the transition zone, the peripheral zone, and the central zone. In contrast,
the mouse prostate is composed of four separate lobes surrounding the urethra:
ventral, lateral, dorsal, and anterior. The dorsal and lateral lobes are often referred
to collectively as dorsolateral. Despite being similar in molecular characteristics, the
mouse and human prostates have significant anatomical and histological
differences. Genomic data from microarray analysis suggests that the peripheral
zone, from which the majority of prostate cancers arise in humans, is most similar to
the dorsolateral prostate57,58. Therefore, orthotopic mouse xenografts should be
standardized by injection of cancer cells into the dorsolateral prostate to most
accurately reflect human disease. However, even so, there is limited evidence that
a dorsolateral origin of prostate tumors is, in fact, very similar to human prostate
cancer.
In this study, I two hypotheses. The first is that different populations of AMPK
are located at distinct compartments within the cell, and each of these populations
can be activated by a distinct upstream stimulus. Furthermore, I hypothesize that this
context-dependent response determines the net outcome of AMPK activity in cancer
progression. I am studying this in several ways by: (1) investigating how distinct
populations of AMPK are activated by different stimuli, (2) testing the functional role(s)
of different subcellular AMPK populations and (3) demonstrating how the alpha
subunit isoform present in the AMPK trimer determines its function in prostate cancer
biology. My second hypothesis is that a mouse model that metastasizes reliably to
the bone can be developed by orthotopic injection of prostate cancer cells into
immune compromised, castrated mice. To do this, I compare organ tropism of
10

prostate cancer in castrated or intact immune compromised mice after orthotopic or
subcutaneous injection of human prostate cancer cells. Together, the goal of these
studies is to contribute to the advancement of prostate cancer research through
targeting pathways activated in advanced disease, as well as improving the current
landscape of mouse models of prostate cancer.
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CHAPTER 2: MATERIALS AND METHODS

2.1: Cell lines and reagents
LNCaP and C4-2 were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured according to ATCC protocols. C4-2B and C4-2BLT (gift from Dr. Sue-Hwa Lin, UT MD Anderson Cancer Center) were cultured as
previously described59. Cell lines were maintained without any addition of
antibiotics, validated by STR profiling (University of Texas MD Anderson Cancer
Center Cell Culture Core) and tested for mycoplasma upon thawing out fresh vials.
The synthetic androgen methyltrienolone (R1881) was purchased from PerkinElmer
(Naperville, IL, USA; Cat # NLP005005MG). Doxycycline hyclate (Cat # D9891),
puromycin (Cat # P8833), and polybrene (Cat # TR-1003) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). D-luciferin sodium salt (cat # LUCNA-1G) was
purchased from GoldBio, and 30mg/ml stock solution was maintained at -20°C.

2.2: Xenografts
All animal experiments were approved by and conducted under the Institutional
Animal Care and Use Committee (IACUC) at the University of Texas MD Anderson
Cancer Center (MDACC) according to NIH and institutional guidelines. Tumor
volume was calculated by the formula: (length x width2)/2. Xenografts were
performed on 8-10-week old male NSG mice obtained from either The Jackson
Laboratory (Bar Harbor, ME, USA; Cat # 005557) or MDACC Experimental
Radiation Oncology Breeding Core. 1x106 C4-2B-LT cells in Matrigel® 1:1 vol/vol
(Corning, Corning, NY, USA; Cat # 356231) were injected either orthotopically (total
12

25ul cell solution) into the dorsolateral prostate, or subcutaneously (total 100ul cell
solution) into the flank. Sham surgeries were performed on mice that did not require
surgery.

2.3: Histology and immunostaining
Organs and tumors were immediately fixed in 4% PFA overnight at 4°C. For
staining, samples were dehydrated and embedded in paraffin (MDACC Research
Histology Core Laboratory). Paraffin slides were then rehydrated and further
processed with antigen retrieval in citrate buffer (DAKO, Santa Clara, CA, USA; Cat
# S169984-2). Peroxidase blocking was performed in 1% H2O2 plus 10% methanol
solution. After washing with PBST (PBS with 0.02% Tween 20), secondary
antibodies (Mouse-on-Mouse HRP Polymer, Biocare Medical, CA, USA, Cat#:
MM620; SuperBoost™ Goat anti-Rabbit Poly HRP, Thermo Fisher Scientific,
Waltham, MA, USA; Cat # B40962) were incubated for 30 minutes. Sections were
developed by DAB (Vectorlabs, Burlingame, CA, USA; Cat # SK-4100) and imaged
on a Nikon Eclipse Ci microscope.

2.4: Expression vectors and sgRNA design
CRISPR/Cas9 cells were developed with the lentiCRISPRv2 construct60. The
gRNAs targeting PRKAA1 and PRKAA2 were developed using ChopChop
(https://chopchop.cbu.uib.no/).

2.5: Generation of overexpression CRISPR/Cas9 KO cells
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LentiCRISPRv2 was co-transfected with lentiviral packaging plasmids into 80%
confluent HEK293T cells using Lipofectamine 2000. After 6 hours, media was
changed to DMEM with 10% FBS and 1% BSA. After 48 hours, supernatants were
harvested, filtered, and added to target cells with 7ug/ml polybrene. After 24 hours,
fresh media with 1ug/ml puromycin was used to select for sgRNA expressing target
cells. Then, single clones were isolated to establish knockout cells. Clones were
validated by sequencing and western blot.

2.6: Western blot
Cells were harvested in RIPA lysis buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with Complete
Protease Inhibitor Cocktail (Sigma, Cat # 11697498001) and PhosSTOP
phosphatase inhibitor (Roche, Cat # 4906845001). Immunoblotting was performed
with the following primary antibodies: ULK1 (Cat # 4773), p-ULK1(S555), AMPK
(Cat # 2793), p-AMPK(T172) (Cat #: 2535), CAMKK2 (Cat # 16810), ACC (Cat #
3676), p-ACC (Cat # 3661), KU80 (Cat # 2180) from Cell Signaling Technology;
CAMKK2 (Cat #: HPA017389), GAPDH (Cat #: G8795) from Sigma; AR (Cat # sc7305) from Santa Cruz, AMPKα1 (Cat # MAB3197), AMPKα2 (Cat # AF2850) from
R&D.

2.7: Proliferation assays
Proliferation assays were carried out as previously described by measuring the
cellular double-stranded DNA content using a fluorescent DNA stain61. Transfection
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was done with Lipofectamine 2000 tranfection reagent in OptiMEM media.
Fluorescence was read at excitation 360 and emission 460.

2.8: Immunofluorescence microscopy
Cells were fixed with 4%PFA and permeabilized with 0.1% Triton. Images were
captured using the Olympus BX51 fluorescence microscope and cellSense imaging
software. Images were compiled and analyzed in ImageJ. Immunoflurescence
staining was performed with the following primary antibodies: AMPKα1 (Cat #
MAB3197) and AMPKα2 (Cat # AF2850) from Cell Signaling Technologies; and the
following secondary antibodies: Donkey anti-mouse AlexaFluor 568 (Cat # A10037)
and Donkey anti-goat AlexaFluor 568 (Cat # A11057) from Thermo Fisher Scientific.
Nuclei were counterstained with DAPI (4’,6-diamidino-2-phenylindole).

2.9: Bioluminescence imaging
5-10 minutes before imaging, live mice were injected with 10ul/g of total body
weight of 15mg/ml of D-luciferin in sterile PBS, and imaged on IVIS (in vivo imaging
system) (Perkin Elmer). Dissected organs and tumors were placed in a 24-well plate
and covered with D-luciferin solution and imaged on IVIS.

2.10: Statistical analysis
One-way ANOVA with Tukey’s post-hoc test for multiple comparisons were
performed. The data were analyzed using GraphPad Prism 9.0. All data is
presented as mean +/- standard error of the mean, and P values are <0.05.
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CHAPTER 3: RESULTS

3.1: Different stimuli activate distinct subcellular AMPK populations
Previous studies suggest that distinct populations of AMPK behave
differently in response to stimuli. Organelle-targeted AMPK activity reporters
(AMPKARs) were used to measure AMPK activity at different subcellular
compartments62. AMPKAR is a peptide reporter of Förster resonance energy
transfer (FRET), which measures energy transfer between two fluorescent
chromophores, upon activation by AMPK. AMPKAR has been optimized from its
original form63 and has been genetically encoded with organelle targeting
sequences to either the plasma membrane, cytoplasm, nucleus, mitochondria,
endoplasmic reticulum, Golgi apparatus, or lysosomes62 (collectively called
organelle specific AMPKAR, or osAMPKAR). This study reported that different
organelle-localized populations of AMPK behaved differently in response to diverse
metabolic perturbations62.
I used these genetically encoded AMPKARs to measure spatially and
temporally distinct activation of intracellular AMPK. These reporters have previously
shown that the dynamics of AMPK activation vary between cell compartments in
response to stress62. To investigate this in prostate cancer, I used AMPKAR
targeted to either the cytoplasm (Cyto-AMPKAR) or nucleus (Nuc-AMPKAR) to
measure AMPK activity at these compartments in response to mechanistically
different stimuli: the glycolytic inhibitor 2-deoxyglucose (2-DG), and thapsigargin,
which increases intracellular calcium by blocking calcium uptake into the
endoplasmic reticulum (Figure 1A). I transfected 22Rv1 cells, a model of CRPC,
16

with the Cyto-AMPKAR or Nuc-AMPKAR and observed that thapsigargin rapidly
and transiently activated AMPK activity in both the cytoplasm and the nucleus, while
2-DG caused a gradual, sustained activation of cytoplasmic AMPK, with no effect
on nuclear AMPK (Figure 1B).
Next, I knocked down CAMKK2 using a doxycycline-inducible shRNA system
(Figure 2A-C). CAMKK2 is the main upstream kinase of AMPK, and it is known to
be a predominantly cytoplasmic protein. With the knockdown of CAMKK2, there
was a significant decrease in cytoplasmic AMPK activity, with no change in nuclear
AMPK activity (Figure 2D). This is in accordance with our understanding of
CAMKK2 mainly interacting with the cytoplasmic population of AMPK. Together,
these data support my hypothesis that different populations of AMPK (in this case,
nuclear vs. cytoplasmic) are differentially activated depending on the upstream
signal.
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A

B

Figure 1. Different stimuli activate distinct subcellular AMPK populations. (A)
Fluorescent microscopy confirming localization of AMPKAR to cytoplasm (left) or nucleus
(right) (B) AMPK activity quantification by FRET output of cyto-AMPKAR (left) and

nuc-AMPKAR (right). Cells were treated with either thapsigargin (blue) or 2-DG
(orange) at 5 minutes after FRET reading began. SEM is shown.
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B

C

D

Figure 2. CAMKK2 knockdown decreases cytoplasmic AMPK activity. (A)
pINDUCER construct used for CAMKK2 knockdown. (B) Doxycycline-inducible
shCAMKK2 22Rv1 cells were treated with vehicle (PBS) or doxycycline (DOX) for
72 hrs and cell lysates were subject to immunoblot analysis. (C) Fluorescent
microscopy confirming localization of AMPKAR to cytoplasm (left) or nucleus (right).
(D) 22Rv1 shCAMKK2 cells were treated ± 800 µg/ml doxycycline for 3 days and
transfected with either Cyto-AMPKAR or Nuc-AMPKAR. FRET/CFP intensity was
averaged. *p<0.05.
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3.2: Compartmentalized populations of AMPK have diverse functions
Next, I investigated how different spatially located subpopulations of AMPK
contribute to cell growth. I first used an AMPK inhibitor peptide (AIP) fused to
various organelle targeting sequences62 to perturb AMPK activity at specific
subcellular locations (Figure 3A). The AIP also contains an mCherry sequence
which was used by imaging flow cytometry to confirm correct expression and
subcellular localization of the peptide within the cell (Figure 3B). I transfected
LNCaP cells with either the mCherry backbone, the AIP peptide, or AIP targeted
specifically to the cytoplasm or nucleus, and quantified cell proliferation in response
to R1881, a synthetic androgen. I observed that LNCaP cell proliferation increased
upon inhibition of nuclear AMPK relative to cells with cytoplasmic AMPK inhibition
(Figure 3C). This data further supports the hypothesis that nuclear AMPK is more
tumor suppressive, while cytoplasmic AMPK promotes oncogenic effects.
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A

B

C

Figure 3. Inhibition of AMPK at different subcellular compartments has
opposing effects on prostate cancer cell growth. (A) Constructs were developed
containing an AMPK inhibitor peptide (AIP) sequence fused to an organelletargeting sequence. Schematic of organelle-localized AIP plasmids is shown. (B)
Imaging flow cytometry analysis shows localization of nuclear and cytoplasmic AIP
constructs. (C) LNCaP cells were transfected with mChF, mChF-AIP, Nuc-mChFAIP, or Cyto-mChF-AIP for 24 hours and then treated with vehicle or androgen for 7
days. Relative cell number was analyzed with a DNA stain.
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3.3: Functional differences between AMPKα1 KO, AMPKα2 KO
I have developed AMPKα1 and AMPKα2 CRISPR/Cas9 knockout models of
LNCaP, a hormone-sensitive prostate cancer cell line, and the CRPC cell lines
22Rv1 and C4-2. These cell lines represent early and advanced stages of prostate
cancer, respectively. Using the lentiCRISPR v2 vector60 containing sgRNA
sequences for either PRKAA1 or PRKAA2, I knocked out either gene in these cell
models.
Single cell cloning was performed to create cell lines with no residual protein,
something that is possible in the pooled knockout cell lines. I then confirmed the
PRKAA1 or PRKAA2 knockout cell lines (hereafter referred to as “α1 KO or α2 KO,”
respectively) by western blot (Figure 4A). Given the localization of each subunit to
distinct compartments, I wanted to test the hypothesis that the different isoforms are
involved in activating distinct populations of downstream substrates. I tested this by
measuring the activation of AMPK downstream targets that are known to localize to
either the nucleus (p300) or the cytoplasm (ULK, ACC, and RAPTOR). I observed a
decrease in phosphorylation in the cytoplasmic proteins in the α1 KO cell lines, and
a decrease in the nuclear p300 protein in the α2 KO cell lines (Figure 4B).
Next, I investigated the how the different KO clones behaved in response to
hypoxia. Hypoxia activates AMPK by inhibiting oxidative phosphorylation 64, thereby
increasing the ratio of AMP:ATP within the cell. Parental LNCaP cells, α1 KO cells,
and α2 KO cells were treated with either R1881 or vehicle, and then incubated in
either 5% O2 (normal oxygen) or 1% O2 (low oxygen) in a dedicated hypoxia
chamber. A proliferation assay showed that after 7 days, the α1 KO cells had a
significantly lower cell number relative to the α2 KO cells (Figure 5A-B). This
22

suggested that AMPKα1 may have more of a role in prostate cancer cell growth,
while AMPKα2 may suppress prostate cancer cell growth under conditions of
hypoxia.
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A

B

Figure 4. AMPKα1 and AMPKα2 differentially activate known downstream
AMPK targets. (A) Western blot validating knockout of AMPKα1 and AMPKα2 in
CRISPR knockout cells. (B) Western blot showing the effect on phosphorylation of
AMPK downstream targets in AMPKα1 and AMPKα2 knockout cells.
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B

Figure 5. AMPKα1 and AMPKα2 knockout cells have different responses to
hypoxia. AMPKα1 or AMPKα2 knockout LNCaP cells were treated with either
vehicle or androgen and incubated either in normoxia (A) or hypoxia (B) for 7 days.
Relative cell number was analyzed with a DNA stain. p<0.05
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3.4: AMPKα1 and AMPKα2 localize to distinct cell compartments
Next, I treated LNCaP cells with either vehicle or R1881 and performed cell
fractionation using centrifugation to isolate the nuclear and cytoplasmic cell
compartments. A western blot showed that AMPKα1 was present in the cytoplasm,
while AMPKα2 was in the cytoplasm, and to a lesser extent in the nucleus (Figure
6A). This supports my hypothesis that AMPKα1 is more cytoplasmic, while AMPKα2
may also shuttle to the nucleus.
To further investigate these results, I examined AMPKα1 or AMPKα2
subcellular localization using immunofluorescence microscopy. Using antibodies
specific for either the AMPKα1 or AMPKα2 subunit, I observed that in LNCaP α1
KO cells, the fluorescence staining appeared throughout the cells, while in the α2
KO cells, the fluorescence appeared more nuclear (Figure 6B). Future studies are
needed to confirm the specificities of these antibodies in immunofluorescence
microscopy.
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A

B

Figure 6. AMPKα1 and AMPKα2 isoform localization in prostate cancer cells.
(A) LNCaP cells treated with androgen for 72 hours were subjected to biochemical
fractionation to isolate cytoplasmic and nuclear fractions. (B) LNCaP cells were
immunofluorescently labeled with anti-AMPKα1 (top) or anti-AMPKα2 (bottom) and
DAPI.
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3.5: Bone metastases occur at a high rate in orthotopically injected, castrated
NSG mice
Immunodeficient male mice (NOD-scid IL2Rgammanull) (“NSG”) were
castrated and orthotopically injected (into the dorsolateral lobe of the prostate) with
C4-2B prostate cancer cells labeled with tdTomato and luciferase reporters. C4-2
castrate-resistant cells are derived from LNCaP prostate cancer cells, and C4-2B is
a CRPC cell line derived from cells that have metastasized to bone after castration.
After 6 weeks, the mice were dissected, and isolated organs (brain, heart, liver,
kidneys, lungs, femur, spleen, and lymph nodes) were imaged on the IVIS (in vivo
imaging system) to view presence of metastases. In all 3 mice, bone metastases
were observed. This was a surprising observation as there are no mouse models
that consistently metastasize from the primary site to the bone. I wanted to
investigate this further because the development of a mouse model metastasizing
reliably to bone would be useful in prostate cancer metastasis studies.
To further investigate, I created 4 groups of NSG mice with either orthotopic
or subcutaneous injection, and either castrated or intact (group 1: orthotopic,
castrated; group 2: orthotopic, intact; group 3: subcutaneous, castrated; group 4:
subcutaneous, intact). This would allow me to test the impact of both castration and
route of inoculation on the incidence of bone metastases. The mice were injected
with luciferin and imaged on the IVIS weekly for 6-7 weeks or when the primary
tumor reached 1.5cm3 (Figure 7A). During this time, the primary tumor was
quantified by IVIS as well as caliper measurements for mice with subcutaneous
flank tumors (Figure 7B). Then, the mice were dissected, and the organs were
imaged in a luciferin solution on the IVIS (Figure 8). Several mice died before end
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point, so several groups had fewer than 10 mice. A threshold for a positive
metastatic signal was set at 1 x 104 photons/second (total flux) based on previous
reports65. I observed that 7/8 mice from group 1 (orthotopic, castrated) and 9/10
mice from group 4 (subcutaneous, intact) had bone metastases (Table 1). These
groups had the highest rates of metastasis to bone. The orthotopic, castrated group
is more physiologically relevant to advanced prostate cancer research as it reflects
the castrate-resistant status of advanced disease and dissemination from the
primary site (prostate), so I pursued the development of this bone metastatic mouse
model.
To validate the results from bioluminescent imaging, organs, and bones with
and without observable signal were embedded in paraffin and analyzed by
immunohistochemistry. Samples were stained for human-KU80, a nuclear protein
involved in double strand DNA break repair. This was used to identify the presence
of human cancer cells within the surrounding mouse organ cells. Hematoxylin was
used to counterstain the nuclei. I observed positive staining for h-KU80 in tissues
with positive bioluminescence signal, and negative staining in tissues with negative
bioluminescence (Figure 9).

29

A

B

Figure 7. Quantification of primary tumors in NSG mice. (A) Representative
images of primary tumor bioluminescence. (B) Average radiance (p/s/cm2/sr) was
measured once per week for 6 weeks.
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Subcutaneous
Orthotopic
Figure 8. Quantification of metastases in NSG mice. Total flux (p/s) was
measured for each organ. NTB=non-tumor bearing (mice which were injected with
cancer cells but did not develop a primary tumor).
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Table 1: Metastasis profile of C4-2B-LT xenografts. Presence of metastases was
measured by IVIS. Organs with total flux above threshold (1 x 10 4 p/s) were
considered metastatic. Visceral organs include: brain, heart, lung, liver, kidneys,
spleen, and lymph nodes. TB = tumor-bearing.
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Figure 9. Histological validation of bone metastasis. Femurs from tumor bearing
and non-tumor bearing mice were analyzed by immunohistochemistry and stained
for the human protein KU80.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS
In this study, we provide evidence that AMPK is localized in distinct
compartments within the cell, and furthermore, that these populations are
functionally distinct and non-redundant. This is in consensus with existing evidence
from our lab and others34,62,66. Moreover, we provide evidence to support our
hypothesis that subcellular localization of AMPK is related to the isoform
composition of the trimer. We have shown by western blot and immunofluorescence
microscopy that AMPKα1 appears in the cytoplasm, while AMPKα2 appears in the
cytoplasm and nucleus. Shuttling of AMPK between the nucleus and cytoplasm
requires a nuclear localization sequence (NLS) or nuclear export sequence (NES)
to transport the protein through the nuclear pore complex. The AMPKα2 subunit
contains both a known NLS and NES50,67. In addition, the AMPKα1 subunit contains
a putative NES50,67.
We are interested in further understanding if and when AMPKα1 and
AMPKα2 shuttle between compartments and how this affects the function of the
complex in prostate cancer progression. To do this, we can use site-directed
mutagenesis followed by live-cell imaging to observe the effects of mutating the
NES and NLS sites, thereby sequestering the isoforms in either the nucleus or
cytoplasm.
Our studies using the AMPK inhibitor peptide (AIP) suggest differences in
functional effects between the cytoplasmic and nuclear populations of AMPK.
Specifically, we show that inhibition of the nuclear population resulted in an increase
in cell growth, while an inhibition of the cytoplasmic population lead to a decrease.
This suggests that nuclear AMPK may behave as more of a tumor suppressor,
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while cytoplasmic AMPK may be more oncogenic. Next, BrdU (a thymidine
analogue that is incorporated into DNA during S phase) will be used to analyze
changes in cell growth by quantification of replicating cells through high-throughput
fluorescent cell imaging.
Our studies using the AMPKAR targeted to the cytoplasm or nucleus showed
us that these populations of AMPK are differentially activated in response to
different stresses, in both a spatial and temporal manner. We will continue to
investigate this using AMPKAR targeted to other organs: ER, Golgi, lysosome,
mitochondria, and plasma membrane. We will activate AMPK by mechanistically
distinct stimuli by using 2-DG, thapsigargin, and oligomycin (an ATP synthase
inhibitor),  androgen, and  CaMKK2 knockdown or overexpression. AMPK has
known downstream targets that are associated with each of these organelles;
therefore, it is important to understand how and when AMPK activates each of
these targets. This may allow us to potentially target those AMPK downstream
pathways activated in prostate cancer, while leaving the tumor suppressive
pathways undisturbed.
CRISPR knockout of each of the AMPK alpha subunit isoforms showed us
that each isoform may preferentially activate distinct groups of downstream targets.
This is in line with our hypothesis that each isoform has separate functions in
prostate cancer progression. To investigate this further, we are developing double
knockout cell lines (PRKAA1 and PRKAA2) that, when coupled with genetic
addbacks to preclude off target effects, will allow us to dissect the role of AMPKα1
and AMPKα2 in prostate cancer cells. Furthermore, we would like to establish
knockout mouse models to observe changes on prostate cancer progression in
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immune intact mice with genetic knockout of either gene. These mice will be
established in the TRAMP (transgenic adenocarcinoma of the mouse prostate)
mouse model in C57BL/6 male mice. While AMPKα1-/- AMPKα2-/- double knockout
mice are embryonic lethal, single knockout mice are viable, albeit with certain
metabolic dysfunctions, often affecting glucose or insulin intolerance68.
The bone metastatic mouse model we are developing will be immensely
important to preclinical studies of prostate cancer progression. We found that
several of the groups tested had high rates of metastasis to bone, which is normally
not common in mouse prostate cancer models. Moving forward, we want to further
dissect what exactly causes this effect. In our experiment, we compared groups with
either castrated or intact mice, and either orthotopically or subcutaneously injected
tumors. We are of the opinion that the castrated, orthotopic model is the most
accurate as it mimics the hormone-sensitivity of advanced disease in men, and the
prostate injection site allows the primary tumor to grow in a microenvironment most
similar to clinical disease. Furthermore, the routes that the metastatic cancer cells
travel to reach the metastatic sites will be mimicked more accurately. Intravenous or
cardiac tumor cell injections are also commonly used in metastasis studies, with an
obvious drawback being that the cells to not travel the same routes as in the organic
development metastases. With all of this in consideration, there is no perfect mouse
representation of human disease, as there are differences in the mouse prostate
microenvironment as well as the microenvironment of the potential metastatic sites.
The IVIS imager is able to measure very small quantities of cancer cells that
may be present anywhere throughout the organ. Other methods of measuring
micrometastases such as fluorescent imaging or immunohistochemistry may miss
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the present of many of these metastases. By imaging the whole organ with
bioluminescence imaging and then validating the positive signal with
immunohistochemistry, we can ensure that we quantify all metastases.
Another important aspect of metastatic tropism that should be investigated is
the immune microenviroment. Disseminated tumor cells can travel to bone marrow
and live there dormant for years before forming metastases. NK cells mature and
differentiate in the bone marrow, and can remain there until recruited to a site of
inflammation. This suggests that they may have an important role in the bone premetastatic niche. There is a known crosstalk between NK cell and bone/immune
cells in the bone premetastatic niche that can affect metastasis69. Furthermore, the
presence of high levels of NK cells correlates with a good prognosis in metastatic
castration resistant prostate cancer patients70. Our study used NSG mice, which are
severely immune compromised, and are deficient in B and T cells as well as NK
cells. Prior studies using C4-2B cells in SCID mice do not have a high rate of bone
metastasis when injected orthotopically or subcutaneously71. We would like to do a
comparison study between NSG and SCID (severe combined immunodeficient)
mice, which while being B and T cell deficient, do contain functional NK (natural
killer) cells. Given the role of NK cells in bone metastasis, we expect NK deficient
mice (NSG) to have a greater rate of metastasis, which would suggest that NK
depletion will increase mouse prostate cancer to bone.
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